Seekyo Therapeutics is a biotechnology company focused on developing next-generation cancer treatments. The company specializes in Tumor Micro Environment (TME) Targeting Smart Chemotherapy, which aims to selectively target tumors while sparing healthy tissues. This approach is designed to reduce adverse effects and improve the quality of life for patients. Seekyo's technological platform offers bespoke optimization of both marketed and in-development drugs, making it a valuable partner for big pharma, biotech companies, and academic institutions. The company operates in the oncology market, primarily targeting solid tumors such as lung, breast, and pancreatic cancers. Seekyo's business model involves collaborating with partners to develop vectors for delivering original payloads and optimizing existing treatments. Revenue is generated through partnerships, research collaborations, and licensing agreements.

Keywords: biotechnology, cancer treatment, smart chemotherapy, tumor targeting, solid tumors, drug optimization, oncology, biotech partnerships, TME targeting, innovative therapy.